secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2026-09-03T12:53:40+00:00
Accession:  0001140361-26-035537
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee completes $10.9B acquisition by AbbVie; shareholders get $135.11/share
-----------------------------------------------------------------------------

- Merger completed Sept 3, 2026; each share converted to $135.11 cash, total equity value ~$10.9B.
- Company to delist from Nasdaq; trading suspended Sept 4, 2026, Form 25 to be filed.
- All directors resigned; new directors from Merger Sub appointed; execs stepped down.
- Parachute payment agreements with named execs, capped at $12.5M aggregate for 280G gross-ups.
- 2023 Equity Incentive Plan and ESPP terminated effective at close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000114036126035537/0001140361-26-035537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000114036126035537/ef20081397_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-035537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer